AI
Alphabet Inc Portfolio holdings
AUM
$2.14B
This Quarter Return
+30.25%
1 Year Return
+56.95%
3 Year Return
+189.16%
5 Year Return
+193.61%
10 Year Return
+303.91%
AUM
$2.16B
AUM Growth
+$2.16B
(+39%)
Cap. Flow
+$142M
Cap. Flow
% of AUM
6.57%
Top 10 Holdings %
Top 10 Hldgs %
88.29%
Holding
46
New
1
Increased
3
Reduced
3
Closed
2
Top Buys
| 1 |
DexCom
DXCM
|
$376M |
| 2 |
Revolution Medicines
RVMD
|
$152M |
| 3 |
VERV
Verve Therapeutics
VERV
|
$25.1M |
| 4 |
Neumora Therapeutics
NMRA
|
$3.5M |
Top Sells
| 1 |
UiPath
PATH
|
$175M |
| 2 |
Oscar Health
OSCR
|
$118M |
| 3 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
$106M |
| 4 |
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
|
$16.3M |
| 5 |
EVLO
Evelo Biosciences, Inc. Common Stock
EVLO
|
$208K |
Sector Composition
| 1 | Healthcare | 48.63% |
| 2 | Technology | 47.2% |
| 3 | Industrials | 4.04% |
| 4 | Consumer Staples | 0.12% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
DexCom
DXCM
$29.5B
| $457M | 21.18% | 3,681,885 +3,027,031 | +462% | +$376M |
|
2
CrowdStrike
CRWD
$106B
| $328M | 15.2% | 1,283,683 | – | – |
|
|
3
UiPath
PATH
$5.95B
| $175M | 8.1% | 7,034,337 -7,034,337 | -50% | -$175M |
|
|
VERV
4
DELISTED
Verve Therapeutics
VERV
| $172M | 7.98% | 12,349,086 +1,800,000 | +17% | +$25.1M |
|
5
GitLab
GTLB
$7.93B
| $167M | 7.73% | 2,647,312 | – | – |
|
|
6
Revolution Medicines
RVMD
$7.1B
| $152M | 7.05% | +5,301,512 | New | +$152M |
|
7
Arm
ARM
$147B
| $147M | 6.83% | 1,960,784 | – | – |
|
8
Snowflake
SNOW
$79.6B
| $107M | 4.94% | 535,604 | – | – |
|
9
Prime Medicine
PRME
$578M
| $105M | 4.87% | 11,862,498 | – | – |
|
10
Freshworks
FRSH
$3.93B
| $94.8M | 4.4% | 4,035,595 | – | – |
|
11
Planet Labs
PL
$2.15B
| $78.9M | 3.66% | 31,942,641 | – | – |
|
12
Invivyd
IVVD
$204M
| $22.4M | 1.04% | 5,680,785 | – | – |
|
13
Relay Therapeutics
RLAY
$619M
| $17.3M | 0.8% | 1,568,753 | – | – |
|
|
14
Oscar Health
OSCR
$4.31B
| $14.9M | 0.69% | 1,629,087 -12,848,287 | -89% | -$118M |
|
15
RAPT Therapeutics
RAPT
$188M
| $13.4M | 0.62% | 540,270 | – | – |
|
16
Sana Biotechnology
SANA
$777M
| $11.5M | 0.53% | 2,812,500 | – | – |
|
17
Lyell Immunopharma
LYEL
$213M
| $11.4M | 0.53% | 5,865,125 | – | – |
|
18
Beam Therapeutics
BEAM
$1.66B
| $8.75M | 0.41% | 321,604 | – | – |
|
|
DM
19
DELISTED
Desktop Metal, Inc.
DM
| $8.29M | 0.38% | 11,048,730 | – | – |
|
20
Monte Rosa Therapeutics
GLUE
$296M
| $8.27M | 0.38% | 1,464,015 | – | – |
|
21
Illumina
ILMN
$15.8B
| $7.45M | 0.35% | 53,470 | – | – |
|
|
22
Neumora Therapeutics
NMRA
$280M
| $6.9M | 0.32% | 404,732 +205,124 | +103% | +$3.5M |
|
23
TScan Therapeutics
TCRX
$102M
| $6.28M | 0.29% | 1,077,080 | – | – |
|
|
BRNS
24
Barinthus Biotherapeutics
BRNS
$45.6M
| $5.59M | 0.26% | 1,513,644 | – | – |
|
25
Vera Therapeutics
VERA
$1.38B
| $4.64M | 0.22% | 301,580 | – | – |
|